Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.32 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449682 | 1.00 | MGLL (0.35) | MGLLDDB1CRBNACSL1LMNA | |
| SCHEMBL2778540 | 1.00 | MGLL (0.35) | MGLLDDB1CRBNACSL1LMNA | |
| SCHEMBL2777152 | 1.00 | MGLL (0.35) | MGLLDDB1CRBNACSL1LMNA | |
| SCHEMBL2779946 | 0.91 | MGLL (0.38) | MGLLDDB1CRBNLMNADRD2 | |
| SCHEMBL2776594 | 0.91 | MGLL (0.38) | MGLLDDB1CRBNLMNADRD2 | |
| SCHEMBL2776591 | 0.91 | MGLL (0.38) | MGLLDDB1CRBNLMNADRD2 | |
| SCHEMBL2449681 | 0.88 | FFAR4 (0.37) | MGLL | |
| SCHEMBL2776523 | 0.88 | TSHR (0.37) | MGLLLMNA | |
| SCHEMBL2778370 | 0.88 | TSHR (0.37) | MGLLLMNA | |
| SCHEMBL2776522 | 0.88 | TSHR (0.37) | MGLLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | MGLL 833/4885DDB1 2862/4885CRBN 3833/4885 |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR3 | MGLL 1965/4885DDB1 2866/4885CRBN 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.